Asthma and lower airway disease
SMART isn't

https://doi.org/10.1016/j.jaci.2010.01.019Get rights and content

References (13)

There are more references available in the full text version of this article.

Cited by (4)

  • Advances in pediatric asthma in 2010: Addressing the major issues

    2011, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    They also noted that budesonide/formoterol maintenance and reliever therapy reduces exacerbations versus comparators and achieves at least similar control. Chapman,79 in an associated editorial, pointed out that the data from this study using as-needed combination therapy indicated that although severe exacerbations occurred less frequently, they occurred often enough to be significant and an ongoing concern. He believed that despite the availability of newer medications and formulations, there is no evidence that life-saving strategies of symptom prevention should be abandoned for a program of symptom-driven care.

  • Advances in adult asthma diagnosis and treatment and HEDQ in 2010

    2011, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    In asthmatic patients with fixed obstruction, sputum eosinophil counts and FeNO levels correlated with FEV1 decrease, whereas in patients with COPD, sputum neutrophil counts were inversely correlated with FEV1 decrease. Controversy over the safety of long-acting β-agonists (LABAs) continues.37-42 In February 2010, the US Food and Drug Administration required more restrictive labeling of LABAs and LABA-containing medications.39,40

  • Update on asthma step-therapy

    2010, Allergy and Asthma Proceedings

Disclosure of potential conflict of interest: K. R. Chapman has consulted, has done contract research, and has done CME for AstraZeneca, GlaxoSmithKline, Novartis, and Telacris; has consulted and done contract research for Boehringer Ingelheim, Nycomed, Roche, and Schering Plough; has done contract research for CSL Behring and Pharangenix; has done CME for Grifols; has consulted and has done CME for Pfizer; and has received research support from CIHR, GlaxoSmithKline, and Imperial Oil.

View full text